BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12038703)

  • 21. Association of progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer.
    Govindan S; Ahmad SN; Vedicherla B; Kodati V; Jahan P; Rao KP; Ahuja YR; Hasan Q
    Cancer Biomark; 2007; 3(2):73-8. PubMed ID: 17522428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
    Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
    J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
    Huiping C; Jonasson JG; Agnarsson BA; Sigbjornsdottir BI; Huebner K; Ingvarsson S
    Eur J Cancer; 2000 Aug; 36(12):1552-7. PubMed ID: 10930803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progesterone receptor variants associated with the PROGINS haplotype exhibit functional properties similar to those of wild-type progesterone receptor.
    Stenzig J; Schweikert A; Piasecki A; Höppner G; Eschenhagen T; Rau T
    Pharmacogenet Genomics; 2012 Aug; 22(8):629-41. PubMed ID: 22722322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development.
    Junqueira MG; da Silva ID; Nogueira-de-Souza NC; Carvalho CV; Leite DB; Gomes MT; Baracat EC; Lopes LA; Nicolau SM; Gonçalves WJ
    Int J Gynecol Cancer; 2007; 17(1):229-32. PubMed ID: 17291258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.
    Wagner TM; Möslinger RA; Muhr D; Langbauer G; Hirtenlehner K; Concin H; Doeller W; Haid A; Lang AH; Mayer P; Ropp E; Kubista E; Amirimani B; Helbich T; Becherer A; Scheiner O; Breiteneder H; Borg A; Devilee P; Oefner P; Zielinski C
    Int J Cancer; 1998 Jul; 77(3):354-60. PubMed ID: 9663595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of heterozygosity in bilateral breast cancer.
    Kollias J; Man S; Marafie M; Carpenter K; Pinder S; Ellis IO; Blamey RW; Cross G; Brook JD
    Breast Cancer Res Treat; 2000 Dec; 64(3):241-51. PubMed ID: 11200774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the human progesterone receptor gene polymorphism PROGINS in Austrian ovarian cancer patients.
    Whittemore AS; McGuire V
    Int J Cancer; 2002 Sep; 101(2):202; author reply 203. PubMed ID: 12210000
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of Novel Breast Cancer Risk Loci.
    Chan CHT; Munusamy P; Loke SY; Koh GL; Wong ESY; Law HY; Yoon CS; Tan MH; Yap YS; Ang P; Lee ASG
    Cancer Res; 2017 Oct; 77(19):5428-5437. PubMed ID: 28775167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
    Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
    J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay.
    Chae BJ; Bae JS; Yim HW; Lee A; Song BJ; Jeon HM; Chun MH; Jung SS
    Pathology; 2011 Apr; 43(3):248-53. PubMed ID: 21436635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3.
    Hampton GM; Mannermaa A; Winqvist R; Alavaikko M; Blanco G; Taskinen PJ; Kiviniemi H; Newsham I; Cavenee WK; Evans GA
    Cancer Res; 1994 Sep; 54(17):4586-9. PubMed ID: 8062246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MMP-2 -735 C allele is a risk factor for susceptibility to breast cancer.
    Yari K; Rahimi Z; Moradi MT; Rahimi Z
    Asian Pac J Cancer Prev; 2014; 15(15):6199-203. PubMed ID: 25124598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of heterozygosity and microsatellite instability at RAD52 and RAD54 loci in breast cancer.
    Nowacka-Zawisza M; Bryś M; Hanna RM; Zadrozny M; Kulig A; Krajewska WM
    Pol J Pathol; 2006; 57(2):83-9. PubMed ID: 17019970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.
    Larson PS; Schlechter BL; King CL; Yang Q; Glass CN; Mack C; Pistey R; de Las Morenas A; Rosenberg CL
    BMC Cancer; 2008 Mar; 8():68. PubMed ID: 18325103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allelic loss of chromosomal arm 8p in breast cancer progression.
    Anbazhagan R; Fujii H; Gabrielson E
    Am J Pathol; 1998 Mar; 152(3):815-9. PubMed ID: 9502423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
    Beckmann MW; Picard F; An HX; van Roeyen CR; Dominik SI; Mosny DS; Schnürch HG; Bender HG; Niederacher D
    Br J Cancer; 1996 May; 73(10):1220-6. PubMed ID: 8630282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
    Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.